Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron develops biologic medicines including the eye treatment Eylea and the immunology drug Dupixent.
Health Care stock comparison
REGN vs VRTX: which business are you actually underwriting?
Compare Regeneron Pharmaceuticals, Inc. with Vertex Pharmaceuticals Incorporated using their business models, SEC classifications, fiscal calendars, current primary filings, and the research questions that matter. This is a thesis framework—not a price target or automatic winner.
- Sector
- Health
- Industry
- Same SIC
- Shared themes
- 0
- Updated
- 2026-02-13
REGN vs VRTX: quick comparison
| Company fact | REGN | VRTX |
|---|---|---|
| Company | Regeneron Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
| Exchange | NASDAQ | NASDAQ |
| SEC industry | Pharmaceutical Preparations | Pharmaceutical Preparations |
| Fiscal year-end | December 31 | December 31 |
| Latest annual filing | 10-K · 2026-02-04 | 10-K · 2026-02-13 |
REGN vs VRTX: audited financials
REGN reported about 1.2× the revenue of VRTX in the latest audited fiscal year. On profitability, VRTX converted a larger share of revenue into net income (32.9% versus 31.4%). Scale and margin are starting facts for the thesis, not the verdict.
| Metric | REGN | VRTX |
|---|---|---|
| Revenue | $14.3B | $12.0B |
| Net income | $4.5B | $4.0B |
| Operating cash flow | $5.0B | $3.6B |
| Diluted EPS | $41.48 | $15.32 |
| Net margin | 31.4% | 32.9% |
REGN: FY ending 2025-12-31 · VRTX: FY ending 2025-12-31. Figures as tagged in each issuer's SEC XBRL filing; fiscal calendars may not align.
How the businesses differ
Why this pair belongs in the comparison set
REGN and VRTX share the SEC industry classification “Pharmaceutical Preparations,” giving the comparison a primary-source operating relationship. A shared classification or theme makes the pair useful for a defined research question; it does not mean the companies have identical products, economics, or risks.
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals develops therapies for cystic fibrosis and other serious diseases including gene-based treatments.
The useful starting point is not which ticker has performed better. It is whether the two companies convert the same economic forces into revenue and cash flow in the same way. REGN is classified by the SEC as Pharmaceutical Preparations, while VRTX is classified as Pharmaceutical Preparations. The matching industry code strengthens the peer comparison, although product mix can still differ materially.
Members-only research
What members are reading this month
Sep 22, 2026
Meta jumped 11%. What must happen next to justify the price?A member research report on Meta’s AI rally: Muse, subscription economics, the cash-flow burden, legal costs and the earnings assumptions behind the new price.
Feb 23, 2026
Newmont and the gap between a gold rally and shareholder cashA February 23, 2026 historical cutoff tests whether portfolio simplification and cost control could turn stronger gold economics into cash.
The thesis, the numbers behind it, and what would break it. Full access is $15 a month.
Read the full researchWhich thesis does each company fit?
Use the distinction below to decide which filing deserves deeper work. It is a research routing rule, not a recommendation or prediction.
Study REGN when…
- Drug approvals and clinical-trial readouts
- Medicare and drug-pricing policy
- Demographics and an aging population
- GLP-1 and obesity-drug demand
Study VRTX when…
- Drug approvals and clinical-trial readouts
- Medicare and drug-pricing policy
- Demographics and an aging population
- GLP-1 and obesity-drug demand
Shared research themes
Pharmaceutical Preparations (SEC industry)
SEC filing comparison and disclosure evidence
Start with primary filings because fiscal calendars and accounting presentation can make superficially similar quarters incomparable.REGN's fiscal year ends December 31, while VRTX's ends December 31. Normalize the reporting periods before comparing growth, margins, capital intensity, or guidance.
The current verified House and Senate snapshot contains 14matched transaction rows for REGNand 14 for VRTX. These delayed, range-based disclosures can identify a filing to inspect; they do not establish motive, conviction, or a real-time trading signal.
REGN primary filings
VRTX primary filings
What this comparison cannot tell you
This page does not contain licensed live prices, a valuation model, earnings estimates, portfolio constraints, or a forecast of future returns. SEC classifications can be broad, company descriptions can lag strategic change, and the latest annual filing may predate a material acquisition or divestiture. Read subsequent quarterly and current reports before making a decision.
A stronger business is not automatically the better stock. Starting valuation, expectations, capital structure, cyclicality, dilution, and the probability of each thesis determine the investment outcome. Use this comparison to frame the work, then verify the numbers in the linked filings and current company disclosures.
More comparisons involving REGN or VRTX
REGN vs VRTX FAQs
Are REGN and VRTX direct competitors?
Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated share the SEC industry classification “Pharmaceutical Preparations.” That makes the operating comparison relevant, but it does not prove that every product, customer, or revenue stream competes directly.
Which is better, REGN or VRTX?
There is no context-free winner. Compare the operating exposures, filing evidence, valuation, balance sheet, and risks against the specific thesis you are testing. This page deliberately does not turn a static profile into a buy or sell recommendation.
Does this REGN vs VRTX comparison include live prices?
No. Yield Theory does not republish unlicensed real-time market data. The financial figures on this page are the audited annual numbers Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated tagged in their SEC XBRL filings. Use a regulated broker or licensed quote provider for current prices and valuation multiples.
Where does the company information come from?
Company classifications, fiscal year-ends, and filing links come from the SEC EDGAR submissions API snapshot refreshed 2026-09-25. Business summaries and research themes are maintained by Yield Theory.
Data snapshot: SEC EDGAR submissions API, refreshed 2026-09-25. Independent educational research; not investment advice.
A comparison is the setup. The thesis is the call.
REGN vs VRTX shows how the businesses differ. Membership is the monthly sourced view of who could benefit, what could break, and what evidence matters next. $15/month or $150/year.
Members-only research
$15/mo or $150/yr · cancel future renewals anytime · sources included